Table of Contents

Figure S1: Light-induced dissociation of OptoCAR construct.	2
Figure S2: RT-qPCR data for experiments shown in Figure 5.	3
Figure S3: Vector construction and protein sequence of OptoCARs.	4



Figure S1. Light-induced dissociation of OptoCAR construct.

- A The individual plots from the 12 analyzed cells used to prepare Figure 1E are shown without normalization. The ratio of membrane-bound intracellular part of OptoCAR compared to the the cytoplasm is quantified over time. Cells were illuminated after 25 seconds of imaging for 25 seconds to calculate dissociation rate (green) before returning to dark (signaling competent) state to calculate re-association rate (red line). These individual fits were used to calculate the mean rate parameters presented in the main text.
- B The C450G variant of LOV2 was inserted into the OptoCAR and the equivalent experiment as in (A) was performed. No significant decrease in membrane fluorescence was observed with this variant, ruling out phototoxic effects as an explanation for the measured OptoCAR dynamics. Five cell traces are shown, with mean (n=5) presented as red line.



Figure S2. RT-qPCR data for experiments shown in Figure 5.

- A The cRQ values for the RT-qPCR datasets maintained in the dark state are presented without additional scaling. The mRNA levels were calculated relative to the 0 min sample and then normalized to the geometric mean of *PGK1* and *GAPDH* mRNA (housekeeping genes) to control for variable cDNA quantity, forming the cRQ values. Each biological replicate is colored separately and the gene name for each dataset is given in the boxes above plots.
- B Equivalent plots as in (A) but now showing the light-induced cessation of signaling at 3 hours, shown with the blue region.

Α

Myr		P2A SP				
Zdk <mark>ζ-chain</mark>	mScarlet		FKBP	CD86 (Ex&TM)	LOV2	
AsiSI	BamHI	Spel Mlul			Spel	Notl

В

1	MGCGCSSHPE	DDGGSGGSGG	SMVDNKFNKE	KTRAGAEIHS	LPNLNVEQKF	AFIVSLFDDP	SQSANLLAEA	KKLNDAQAPK	TSADAPAYQQ	GQNQLYNELN	100
101	LGRREEYDVL	DKRRGRDPEM	GGKPQRRKNP	QEGLYNELQK	DKMAEAYSEI	GMKGERRRGK	GHDGLYQGLS	TATKDTYDAL	HMQALPPRDP	PVATMVSKGE	200
201	AVIKEFMRFK	VHMEGSMNGH	EFEIEGEGEG	RPYEGTQTAK	LKVTKGGPLP	FSWDILSPQF	MYGSRAFTKH	PADIPDYYKQ	SFPEGFKWER	VMNFEDGGAV	300
301	TVTQDTSLED	GTLIYKVKLR	GTNFPPDGPV	MQKKTMGWEA	STERLYPEDG	VLKGDIKMAL	RLKDGGRYLA	DFKTTYKAKK	PVQMPGAYNV	DRKLDITSHN	400
401	EDYTVVEQYE	RSEGRHSTGG	MDELYKTSYQ	GPGATNFSLL	KQAGDVEENP	GPTRMGVKVL	FALICIAVAE	AKYPYDVPDY	AGVQVETISP	GDGRTFPKRG	500
501	QTCVVHYTGM	LEDGKKVDSS	RDRNKPFKFM	LGKQEVIRGW	EEGVAQMSVG	QRAKLTISPD	YAYGATGHPG	IIPPHATLVF	DVELLKLEGG	SGGSGGS LKI	600
601	QAYFNETADL	PCQFANSQNQ	SLSELVVFWQ	DQENLVLNEV	YLGKEKFDSV	HSKYMGRTSF	DSDSWTLRLH	NLQIKDKGLY	QCIIHHKKPT	GMIRIHQMNS	700
701	ELSVLANFSQ	PEIVPISNIT	ENVYINLTCS	SIHGYPEPKK	MSVLLRTKNS	TIEYDGIMQK	SQDNVTELYD	VSISLSVSFP	DVTSNMTIFC	ILETDKTRLL	800
801	SSPFSIELED	PQPPPDHIPW	ITAVLPTVII	CVMVFCLILW	KWKKKKRPRT	SGGSGSLATT	LERIEKNFVI	TDPRLPDNPI	IFASDSFLQL	TEYSREEILG	900
901	RNCRFLOGPE	TDRATVRKIR	DAIDNOTEVT	VOLINYTKSG	KKFWNLFHLO	PMRDOKGDVO	YFIGVOLDGT	EHVRDAAERE	GVMLIKKTAE	NIDEAAKEL*	999

С

pr1: 5'	gtagactagtgg	cggaagcggaagtttggct	actacacttgaacgtattg 3'
---------	--------------	---------------------	------------------------

pr2: 5' ctactagcggccgctcaaagttcttttgccgcctcatc 3'

pr3: 5' tagtaggcgatcgccaccatgggctgtggctgcagc 3'

pr4: 5' cgccagggccctggtaactGgtcttgtacagctcgtccatgc 3'

pr5: 5' gcatggacgagctgtacaagacCagttaccagggccctggcg 3'

- pr6: 5' tagtaggcgatcgccacctggtggataacaaattcaataaagaaaag 3'
- pr7: 5' ctactaggatcccgaggggggggggggg 3'

D

Ε

)	Myr			P2A							
	- D	Zdk <mark>ζ-cł</mark>	nain	mScarlet			αCD19	-CAR (Ex+TM)		LOV2		
	A	siSI	BamHI		Spel	 Mlul			S	pel N	loti	
1	MGCGCSSHPE	DDGGSGGSGG	SMVDNKFNKE	KTRAGAEIHS	LPNLNV	EQKF	AFIVSLFDDP	SQSANLLAEA	KKLNDAQAPK	TSADAPAYQ	Q GQNQLYNELN	100

101	LGRREEYDVL	DKRRGRDPEM	GGKPQRRKNP	QEGLYNELQK	DKMAEAYSEI	GMKGERRRGK	GHDGLYQGLS	TATKDTYDAL	HMQALPPRDP	PVATMVSKGE	200
201	AVIKEFMRFK	VHMEGSMNGH	EFEIEGEGEG	RPYEGTQTAK	LKVTKGGPLP	FSWDILSPQF	MYGSRAFTKH	PADIPDYYKQ	SFPEGFKWER	VMNFEDGGAV	300
301	TVTQDTSLED	GTLIYKVKLR	GTNFPPDGPV	MQKKTMGWEA	STERLYPEDG	VLKGDIKMAL	RLKDGGRYLA	DFKTTYKAKK	PVQMPGAYNV	DRKLDITSHN	400
401	EDYTVVEQYE	RSEGRHSTGG	MDELYKTSYQ	GPGATNFSLL	KQAGDVEENP	GPTRMALPVT	ALLLPLALLL	HAARPDIQMT	QTTSSLSASL	GDRVTISCRA	500
501	SQDISKYLNW	YQQKPDGTVK	LLIYHTSRLH	SGVPSRFSGS	GSGTDYSLTI	SNLEQEDIAT	YFCQQGNTLP	YTFGGGTKLE	ITGGGGSGGG	GSGGGGSEVK	600
601	LQESGPGLVA	PSQSLSVTCT	VSGVSLPDYG	VSWIRQPPRK	GLEWLGVIWG	SETTYYNSAL	KSRLTIIKDN	SKSQVFLKMN	SLQTDDTAIY	YCAKHYYYGG	700
701	SYAMDYWGQG	TSVTVSSTTT	PAPRPPTPAP	TIASQPLSLR	PEACRPAAGG	AVHTRGLDFA	CDIYIWAPLA	GTCGVLLLSL	VITLYCKKKK	RPRTSGGSGS	800
801	LATTLERIEK	NFLITDPRLP	DNPIIFASDS	FLQLTEYSRE	EILGRNCRFL	QGPETDRATV	RKIRDAIDNQ	TEVTVQLINY	TKSGKKFWNL	FHLQPMRDQK	900
901	GDVOYFTGVO	LDGTEHVRDA	AEREGVMLTK	KTAENTDEAA	KEL*						943

Figure S3. Vector construction and protein sequence of OptoCARs.

- A Schematic showing the various components part of the OptoCAR construct as they are arranged in the lentiviral vector used to express the receptor in T cells. Relevant restriction sites are highlighted. Myr denotes myristoylation sequence and SP is signal peptide sequence.
- B Protein sequence of OptoCAR, using colors from (A) to denote different regions. Point mutations in LOV2 domain used for OptoCAR variants are highlighted red.

C Oligonucleotide sequences used in construction of OptoCAR vectors.

- D Schematic showing the various components part of the OptoCAR^{CDI9} construct as they are arranged in the lentiviral vector used to express the receptor in T cells. Relevant restriction sites are highlighted. Myr denotes myristoylation sequence.
- E Protein sequence of OptoCAR^{CD19}, using colors from (D) to denote different regions.